Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058977 | 0.84 | ALDH1A1 (0.46) | ALDH1A1USP2GAAS1PR3KDM4E | |
| SCHEMBL2058978 | 0.84 | ALDH1A1 (0.46) | ALDH1A1USP2GAAS1PR3KDM4E | |
| SCHEMBL2058915 | 0.84 | ALDH1A1 (0.46) | ALDH1A1USP2GAAS1PR3KDM4E | |
| SCHEMBL10107765 | 0.72 | — | — | |
| SCHEMBL28632721 | 0.69 | ALDH1A1 (0.40) | ALDH1A1USP2GAAS1PR3KDM4E | |
| SCHEMBL2058680 | 0.69 | CYP2D6 (0.37) | ALDH1A1USP2GAAS1PR3KDM4E | |
| SCHEMBL12944761 | 0.67 | — | — | |
| SCHEMBL19293546 | 0.67 | ALDH1A1 (0.45) | ALDH1A1USP2GAAS1PR3KDM4E | |
| SCHEMBL20403535 | 0.64 | ALDH1A1 (0.42) | ALDH1A1USP2GAAS1PR3KDM4E | |
| SCHEMBL24088541 | 0.64 | ALDH1A1 (0.45) | ALDH1A1USP2GAAS1PR3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968605-B2 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. (PT) | 2011-06-28 | — | — | US | disclosed |
| US-20080026984-A1 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | ALFAMA - INVESTIGACAO E DESENVOLVIMENTO DE PRODUCTOS FARMACEUTICOS LDA (PT) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080026984-A1 | Methods for treating inflammatory disease by administering aldehydes and derivatives thereof | MPO, TNF, AOX1 | ALDH1A1 7/4885USP2 1486/4885GAA 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.